DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150306

Comparative study of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, and rheumatoid factor predictability in the diagnosis of rheumatoid arthritis

Manoj Kumar, Sumit Chawla, Abhishek Jain

Abstract


Background: Rheumatoid arthritis (RA) is characterized by synovial joint inflammation, which often leads to progressive joint destruction and disability. Several other auto-antibodies specific to RA have been found .Among them, antibodies against cyclic citrullinated peptides (CCP) are useful for diagnosing RA. Antibodies to mutated citrullinated vimentin (MCV) were described recently in RA. The aim of this study was to determine the diagnostic values of ACCP compared to anti-MCV and Rheumatoid Factor in rheumatoid arthritis patients.

Methods: This study included 92 patients with Rheumatoid arthritis (RA) and 35 matching healthy controls. Blood samples were obtained from patients and controls for Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), Rheumatoid factor (RF). Anti-CCP2 and anti-MCV were determined using ELISA technique.

Results: RA group was significantly higher than control group as regard ESR, CRP, RF, Anti-CCP, and Anti- MCV.

Conclusion: It was concluded, compared to ACCP, anti-MCV has approximately the same accuracy for the diagnosis of rheumatoid arthritis but higher than Rheumatoid Factor.

Level of Evidence: Level II, prospective study, as per guidelines for authors.

 


Keywords


Anti-cyclic citrullinated peptide (anti-CCP2), Anticitrullinated vimentin antibody (anti-CMV), Rheumatoid arthritis (RA)

Full Text:

PDF

References


Pedersen-Lane JH, Zurier RB, Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J Leukoc Biol. 2007;81:934-41.

Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094-108.

Serre G. Autoantibodies to filaggrin/deiminated fibrin (AFA) are useful for the diagnosis and prognosis of rheumatoid arthritis, and are probably involved in the pathophysiology of the disease. Joint Bone Spine. 2001;68:103-5.

Aletaha DK, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College Of Rheumatology/ European League against Rheumatism Collaborative initiative. Ann Rheum Dis. 2010;69:1580-8.

Pruijn GJ, Wiik A, van Venrooij WJ. The Use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2010;12:203.

Nicaise-Roland P, Nogueira L, Demattei C, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies indiagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis. 2013;72:357-62.

Keskin G, Inal A, Keskin D, Pekel A, Baysal O, et al. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis. Protein Pept Lett. 2008;15:314-7.

Sghiri R, Bouajina E, Bargaoui D, et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis. Rheum atal Int. 2008;29:59-62.

Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic vale concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58:36-45.

Wagner E, Skoumal M, Bayerand PM, Klaushofer K. Antibody against mutated citrullinated vimentin: A new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int. 2009;29:1315-21.

Damjanovska L, Thabet MM, Levarth EW, et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis. 2009;69:730-2.

Zhu T, Feng L. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients. Int J Rheum Dis. 2013;16:157-61.

Sariyildiz MA, Batmaz I, Guli Çetinçakmak M, Yıldız I, Nas K, et al. Relationship of the HLA-DRB1 alleles and seropositivity, anti-MCV, functional status and radiological damage in Turkish patients with rheumatoid arthritis. J Back Musculoskelet Rehabil. 2013;26:63-70.

Mikuls TR, O’Dell JR, Stoner JA, Parrish LA, Arend WP, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50:3776-82.

Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti- CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:20-5.

Liu X, Jia R, Zhao J, Li Z. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol. 2009;36:1136-42.

Morbach H, Dannecker H, Kerkau T, Girschick HJ. Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28:800.